Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Name Transcript

Operator

Good afternoon. My title is Jeannie, and I shall be your convention operator in the present day. I wish to welcome you to the Janux Therapeutics Scientific Information Replace Webcast. [Operator Instructions]

I’d now like to show the convention name over to Chad Rubin, Head of Investor Relations for Janux. You might start your convention.

Chad Rubin

Thanks, Jeannie, and good afternoon, everybody. At present, Janux issued a press launch saying interim medical knowledge for the corporate’s JANX007 medical program. This press launch, in the present day’s webcast and corresponding slides can be found on our web site.

Earlier than we start our ready remarks, we wish to remind everybody that sure feedback made by Janux administration on this name will embody forward-looking statements. These forward-looking statements are based mostly on present data, assumptions and expectations which can be topic to vary and contain a lot of dangers and uncertainties that will trigger precise outcomes to vary materially from these contained in such statements. These and different dangers and uncertainties are described in our periodic filings made with the SEC. You might be cautioned to not place undue reliance on our forward-looking statements, and the corporate disclaims any obligation to replace these statements.

With that, I wish to flip the decision over to David Campbell, President and CEO of Janux.

David Campbell
President, CEO & Director